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Background:Molecular assaysare thegold standardmethodsused todiagnoseviral respiratorypathogens.
Pitfalls associated with this technique include limits to the number of targeted pathogens, the require-
ment for continuous monitoring to ensure sensitivity/speciﬁcity is maintained and the need to evolve to
include emerging pathogens. Introducing target independent next generation sequencing (NGS) could
resolve these issues and revolutionise respiratory viral diagnostics.
Objectives: To compare the sensitivity and speciﬁcity of target independent NGS against the current
standard diagnostic test.
Study design: Diagnostic RT-PCR of clinical samples was carried out in parallel with target indepen-
dent NGS. NGS sequences were analyzed to determine the proportion with viral origin and consensus
sequences were used to establish viral genotypes and serotypes where applicable.
Results: 89 nasopharyngeal swabs were tested. A viral pathogen was detected in 43% of samples by NGS
and 54% by RT-PCR. All NGS viral detections were conﬁrmed by RT-PCR.
Conclusions: Target independent NGS can detect viral pathogens in clinical samples. Where viruses were
detected by RT-PCR alone the Ct value was higher than those detected by both assays, suggesting an NGS
detection cut-off – Ct =32. The sensitivity and speciﬁcity of NGS comparedwith RT-PCRwas 78% and 80%
respectively. This is lower than current diagnostic assays but NGS provided full genome sequences in
some cases, allowing determination of viral subtype and serotype. Sequencing technology is improving
rapidly and it is likely thatwithin a short period of time sequencing depthwill increase in-turn improving
test sensitivity.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Background
Virus speciﬁc molecular assays such as real-time PCR (RT-PCR)
are now considered the gold standard in the diagnosis of viral
respiratory tract infections. They are rapid, relatively inexpensive
and offer increased sensitivity and speciﬁcity over prior techniques
Abbreviations: RT-PCR, real-time polymerase chain reaction; NGS, next gener-
ation sequencing; NPS, nasopharyngeal swab; VTM, viral transport medium; HRV,
human rhinovirus; IFA, inﬂuenzaA; IFB, inﬂuenzaB;RSV, respiratory syncytial virus;
ADV, adenovirus; hMPV, humanmetapneumovirus; PIV-1-4, parainﬂuenza virus 1-
4; HCoV, human coronavirus;WoSSVC,West of Scotland Specialist Virology Center;
HEV, human enterovirus; Ct, cycle threshold; BLAST, basic local alignment search
tool; TRT, turn-around time.
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such as virus culture anddirect immunoﬂuorescence. Assays can be
developed quickly to detect novel/emerging pathogens and can be
combined to identifymultiplemicrobiological pathogens in a single
test. Yet there is a limit to the number of targets, usually up to four,
which canbe included in an in-house test before compromising test
sensitivity. As a result, diagnostic laboratoriesmust develop a panel
of multiplex tests in order to detect the whole range of pathogens.
Also, as for all PCRbased assays, detection is basedon targeting con-
served regions of the pathogen genome and mutations can lead to
reduced sensitivity or false negative results. Furthermore, only the
targeted pathogens included in the assay will be identiﬁed, there-
fore atypical or emerging pathogens will generally evade detection
by PCR. Although commercial PCR based tests [1] are available that
overcome some of the pitfalls associated with in-house tests, they
remain PCR based technologies and as a result suffer from the same
sequence based pitfalls outlined above.
http://dx.doi.org/10.1016/j.jcv.2015.06.082
1386-6532/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Introducing NGS into a diagnostic setting may revolutionize
the investigation of respiratory infections. Combining sequence
independent ampliﬁcation with NGS will potentially detect viral
and non-viral pathogens within a clinical specimen without
actively targeting them, while simultaneously analyzing the
genetic sequence. NGS is established in virus discovery, whole
genome studies andmetagenome studies [2–4] thus the simultane-
ous detection of multiple different pathogens with this technique
is possible. However the efﬁcacy and feasibility of employing such
techniques in a diagnostic setting requires further study.
2. Objectives
Here we present a pilot study that compares current diagnos-
tic techniques, namely RT-PCR with NGS in the detection of RNA
viruses in respiratory samples from individuals symptomatic of a
respiratory illness.
3. Study design
3.1. Samples
Eighty nine nasopharyngeal swabs (NPS) were collected from
adults with upper respiratory tract infections between May 2010
and October 2011. Samples were collected as part of the VIDARIS
trial, a random subset of which were used in this study. It should
be noted that over half of the participants in this trial were vac-
cinated against inﬂuenza. Ethical approval was provided by the
UpperSouthBRegional EthicsCommittee.All participantsprovided
written informed consent [5]. Swabs were stored in viral trans-
port media (VTM) at −80 ◦C until testing. The VTM was thawed at
37 ◦C and centrifuged at 1500× g for 10min to remove debris. Total
nucleic acids were extracted from 200l of the supernatant (Mag-
Jet Viral DNA and RNA kit, Thermo Scientiﬁc) and eluted in 100l
of water.
3.2. Next generation sequencing method
A 20l aliquot of the extract was treatedwith DNAse 4U (Turbo
DNAse 2U/l, Life technologies) for 30min at 37 ◦C. RNA was puri-
ﬁed from the reactionusingRNACleanXPbeads (Agencourt), eluted
in 15l of water and reverse transcription carried out using Max-
imaMinus H (Thermoﬁsher) at 50 ◦C for 60minwith 0.2pM primer
FR26RV-N (5′ GCC GGA GCT CTG CAG ATA TCN NNNNN 3′). Second
strand cDNAwas synthesised (NEBNext mRNA 2nd Strand Synthe-
sis, NewEnglandBiolabs) and the reactionpuriﬁedwithAmpureXP
beads (Agencourt). Sequence-independent singleprimerampliﬁca-
tion (SISPA)was carriedoutwith theAdvantage2PCRkit (Clontech)
and 0.2pM primer FR20RV (5′ GCC GGA GCT CTG CAG ATA TC 3′).
The PCR product was puriﬁed with Ampure XP beads (Agencourt)
and quantiﬁed (Qubit HSDNA, Life Technologies). 1 ng of cDNAwas
used to prepare barcoded sequencing libraries with the Nextera XT
DNA Sample Prep kit (Illumina) and indices from the Nextera XT
Index Kit as per the manufacturer’s instructions. Up to 24 sample
libraries were pooled per sequencing run and 151bp paired-end
reads were generated on the Illumina MiSeq.
3.3. Bioinformatic analysis
Sequencing adapters and low quality sequencing reads
were removed (Trim Galore!, Babraham Bioinformatics) and
low–complexity reads ﬁltered out (PrinSeq [6]). High quality
paired-end sequences were retained for downstream analy-
ses. These sequences were mapped to a database containing a
human genome and cDNA references, to remove host sequences.
Unmapped sequences were entered into the Metamos pipeline [7]
which employs multiple de novo assemblers with k-mer optimi-
sation to assemble contigs. The contigs from the most effective
assembly were then taxonomically classiﬁed using the Basic Local
Alignment Search Tool (BLAST) against the GenBank nucleotide
and non-redundant databases (cut off E value 0.001). Identical
sequences between samples were removed using BedTools and
unique sequences were retained for further analysis. Sequenced
reads were then mapped back to the top taxonomic hit for
each sample and visualized using Tablet [8], to quantify viral
reads within each sample and generate a consensus sequence.
Where appropriate, greater than 90% of reference genome cover-
age, the consensus sequences were aligned with known reference
sequences and phylogenetic analysis carried out using MEGA6 [9].
Taxonomic hits were compared with the results of the diagnostic
qRT-PCR (Table 1).
3.4. Diagnostic in-house RT-PCR methods
40l of the nucleic acid extract was then screened for human
rhinovirus (HRV), inﬂuenza A/B (IFA/IFB), respiratory syncytial
virus (RSV), adenovirus (ADV), human metapneumovirus (hMPV),
parainﬂuenzavirus 1–4 (PIV 1–4), coronaviruses (HCoV) HKU1,
NL63, OC43 and 229E and Mycoplasma pneumonia using the rou-
tine diagnostic qRT-PCR at theWest of Scotland Specialist Virology
Centre (WoSSVC) as previously described [10].
4. Results
4.1. Next generation sequencing
The average number of sequences generated per sample was
∼660,640 (range 30,872–1,278,122) after quality trimming and
ﬁltering. Viral contigs were found in 53/89 samples but follow-
ing removal of duplicate reads this was reduced to 46/89. In
a subset of samples (n=8), there were fewer than 10 unique
viral reads detected by the NGS assay alone. Due to the low
number of reads we deemed these to be negative by NGS.
The viral sequences detected in the remaining 38 samples
belonged to the Picornaviridae, Coronaviridae, Paramyxoviri-
dae and Orthomyxoviridae (Table 1). No mixed infections were
detected by NGS.
Picornaviruses were most frequently detected (n=21) and clas-
siﬁed as HRV in 20/21 and enterovirus (HEV) in 1/21 cases. These
could be subdivided into 3 rhinovirus species, A (11/21), B (4/21),
C (5/21) and HEV D. Picornavirus sequences generated by NGS
showedhigh similarity at thenucleotide level to referencegenomes
available in the NCBI database, allowing us to assign a serotype
in all but one cases (Table 1). The extent of reference genome
coverage and phylogenetic similarity to reference sequences are
shown in Figs. 1 and 2, respectively. Numerous HRV serotypes and
an HEV-D68 were detected. Human coronaviruses (HCoV) were
detected in nine samples and were found to belong to the fol-
lowing types: HCoV 229E (4/9), HCoV NL63 (3/9) and HCoV OC43
(2/9). Paramyxoviruses were detected in seven samples. These
includedhMPV-B (2/7), PIV-3 (2/7), RSV-A (2/7) andRSV-B (1/7). An
Orthomyxoviruswasdetected inone sample and typedas Inﬂuenza
A H3N2.
All viruses identiﬁed by NGSwere conﬁrmed by qRT-PCR. How-
ever, in eleven cases, virus was identiﬁed by RT-PCR only. This
included the following viruses, ADV (1/11), PIV-2 (1/11), hMPV
(1/11), RSV (2/11), HCoV (3/11) and HRV (3/11). One sample was
found by RT-PCR to contain a mixture of both ADV and HRV. The
NGS method failed to detect the ADV in this sample. Where NGS
conﬁrmed the ﬁndings of the RT-PCR assay the Ct values were sig-
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Table 1
A summary of sequenced reads, real-time PCR and NGS data, including RT-PCR results for all positive samples and the accession number of top taxonomic hits from BLAST
along with reference assembly details.
Sample Total Reads % mapping to
human reference
PCR Ct Taxonomy Accession % reads mapping % genome
covered
Nucleotide
mismatch
1C2 1107488 81.67 HRV 26.75 Enterovirus D-68 AB601885 1.46 14.9 1.4
2A3 1110727 88.23 HCoV 229E 18.14 HCoV 229E JX503060 9.63 99.8 0.6
2A4 311141 98.39 HCoV 229E 20.00 HCoV 229E JX503060 0.16 55.3 0.6
2C3 470840 93.93 HCoV 229E 25.83 HCoV 229E JX503060 0.48 20.0 0.7
2D2 743683 94.07 HCoV 229E 19.74 HCoV 229E JX503060 2.50 73.9 0.6
1D3 801021 96.66 HCoV NL63 27.17 HCoV NL63 KF530112 0.38 11.7 0.5
1E7 426736 92.10 HCoV NL63 24.36 HCoV NL63 JQ765569 0.97 23.3 0.5
1F8 644660 93.24 HCoV NL63 25.22 HCoV NL63 JQ765567 0.03 3.7 0.4
1H1 608153 94.92 HCoV OC43 17.21 HCoV OC43 KF530099 3.48 99.9 1.6
2D5 992040 93.04 HCoV OC43 14.63 HCoV OC43 JN129835 2.70 97.6 0.7
1G6 81749 37.68 hMPV 26.84 hMPV-B KJ627397 1.41 18.5 2.0
2A9 626886 84.12 hMPV 25.68 hMPV-B KF530171 6.35 48.4 3.1
1C7 538412 69.88 HRV 24.93 HRV-A1 JN837694 4.76 87.4 1.2
1D1 1010455 59.82 HRV 20.68 HRV-A1 JN837694 32.03 100 1.9
1D4 1089553 23.19 HRV 19.81 HRV-A1 JN837694 74.67 99.6 2.2
1I5 728425 92.82 HRV 33.66 HRV-A1 JN837694 0.01 39.0 5.6
1H3 413108 83.13 HRV 20.44 HRV-A2 X02316 6.65 96.0 8.1
2C1 816200 91.89 HRV 20.24 HRV-A21 JN837693 5.32 97.9 2.5
1B1 546282 20.17 HRV 18.73 HRV-A49 JN798589 75.48 100 2.5
2B7 596971 95.94 HRV 17.24 HRV-A60 JN798590 1.82 95.3 3.7
2D6 1016390 82.29 HRV 23.07 HRV-A8 FJ445113 6.23 97.0 8.1
1G1 265505 78.73 HRV 28.49 HRV-A90 FJ445167 0.02 2.6 10.8
1C3 1278307 65.56 HRV 28.15 HRV-A97 FJ445172 0.31 20.9 8.7
1I8 1132106 99.02 HRV 27.85 HRV-B27 JF285309 0.01 6.7 3.7
1I4 641357 98.15 HRV 26.01 HRV-B3 JF285331 0.64 97.2 2.4
1H7 657627 56.80 HRV 19.39 HRV-B4 JN798573 39.08 99.7 1.4
1B2 638257 93.07 HRV 26.78 HRV-B92 FJ445169 2.53 56.4 7.5
1I6 1063930 57.27 HRV 29.11 HRV-C (UTR) JX129433 2.92 N/A 2.3
2A6 1056405 83.90 HRV 23.12 HRV-C11 EU840952 0.29 27.2 8.9
1E1 758165 61.76 HRV 20.1 HRV-C15 GU219984 33.93 100 2.0
1E8 887501 96.50 HRV 25.09 HRV-C15 GU219984 0.06 29.7 2.5
1I2 710612 60.67 HRV 19.80 HRV-C17 JN815240 33.29 99.1 3.8
1B8 818055 96.78 Inﬂuenza A 22.34 Inﬂuenza A H3N2 KJ942712 0.03 30.6–60.3 various
1B5 696929 50.67 PIV-3 27.57 PIV-3 KJ672618 5.62 5.0 0.5
1G2 309778 78.95 PIV-3 28.09 PIV-3 KJ672606 0.04 2.8 0.6
1E3 700028 93.78 RSV 20.84 RSVA KJ627329 3.71 91.0 0.7
1F1 322516 85.54 RSV 25.08 RSVA KF826849 3.79 54.6 0.5
2B4 612887 55.78 RSV 19.32 RSVB JX576741 40.52 99.3 2.0
1G1 265505 78.73 Adeno 35.1 N/A
2A2 745105 98.00 HCoV 229E 32.35 N/A
2C4 759226 98.06 HCoV 229E 33.84 N/A
2D3 765913 89.42 HCoV OC43 24.05 N/A
1C9 837310 47.23 hMPV 35.51 N/A
1B7 537522 62.21 HRV 28.94 N/A
1F7 236596 70.59 HRV 28.03 N/A
2B9 569654 76.13 HRV 33.31 N/A
2D4 1034235 96.30 PIV-2 36.07 N/A
1E5 714509 96.87 RSV 30.01 N/A
2B6 854593 77.09 RSV 33.96 N/A
niﬁcantly lower than the group where a virus was detected by the
RT-PCR assay alone (p<0.0001, unpaired t-test), shown in Fig. 3. No
samples contained viral pathogens detected by NGS only.
Further examination of the relationship between the numbers
of viral sequenced reads and the threshold cycle (Ct) value provided
by the RT-PCR assay is shown in Fig. 4. The log of the percentage
of sequenced reads correlates with the Ct value indicating that a
higher viral load is associated with a greater proportion of viral
reads.
Despite sample treatment to enrich for viral RNA, a substantial
number of bacterial transcript sequenceswere generated, however
partial genome ampliﬁcation of bacteria only allows classiﬁcation
to the level of order/family (data not shown).
5. Discussion
As a pilot study designed to assess the utility of NGS as a
method for the detection of respiratory RNA viruses, we compared
an in-house NGSmethod with an established in-house RT-PCR test
using 89 respiratory samples. A viral pathogen was detected by
the NGS method in 38 samples with the RT-PCR conﬁrming these
and detecting a further 11 viruses. Overall, based on these results,
the NGS assay had a sensitivity of 77.55% (95% CI 63.37–88.21%)
and speciﬁcity of 80.49% (95% CI 65.13–91.15%) or 100% (95% CI
91.31–100%) if considering samples with fewer than 10 unique
reads are negative, compared to RT-PCR. It is possible that the sen-
sitivity of NGS detection could vary between virus groups however
the number of detections in this cohort was not powered to assess
each individually.
The 11 NGS negative/RT-PCR positive samples contained virus
at lower Cts compared to those positive by both assays, suggesting
the current NGSmethod has a cut off in the region of Ct 32, approx-
imately 1–2 logs less sensitive than the qRT-PCR method (data
not shown). This ﬁnding is similar to that outlined by Prachayang-
precha et al. At present, this level of sensitivity is not appropriate
for diagnostic services to replace qRT-PCR. Increasing the depth of
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Fig. 1. HRV genome coverage – a graphic visualization of the reference genome
coverage following Bowtie2 alignment of sequencing reads to the top BLAST hit for
each HRV positive sample.
Fig. 2. Neighbor-joining (NJ) phylogenetic tree of full-genome reference sequences
and a subset of theNGS consensus sequenceswith full or near-full reference genome
coverage. The branch annotations represent the bootstrap values (percentage of
1000 samples trees). Sequences generated in this study are shown as circles and
squares.
Fig. 3. Threshold cycle (Ct) values respiratory of samples positive by RT-PCR and
either conﬁrmed or unconﬁrmed by the NGS assay. The bars indicate the mean and
one standard deviation. An unpaired t-test demonstrates a signiﬁcant difference
between the two groups (p<0.0001).
Fig. 4. The percentage of sequenced reads, after quality trimming, mapping to the
taxonomic reference genome determined by BLAST. Linear regression of data, R2
value =0.27 (p=0.0009). This is suggestive of a log relationship between the pro-
portion of reads mapping and the Ct value.
sequencing could improve the sensitivity ofNGS, either by reducing
the multiplexing of samples (i.e., reducing the number of samples
processed per sequencing run) or using an alternative platform
with greater capacity such as the IlluminaNextSeq orHiSeq. Reduc-
ing the contamination of host DNA through host DNA depletion
holds the greatest promise [11] to increase the depth of viral and
microbial DNA as we found up to 99% of reads obtained per sample
were derived from the host.
One of the 11 pathogens not detected by the NGS method was
adenovirus. It is unclear whether this was due to the sensitivity
cut off discussed above (Ct of 35.1) or due to the initial DNAse
step outlined in the method. In future, if this is to be adapted
for the detection of DNA viruses and other non viral causes of
respiratory infection then other ways of enrichment will need
to be sought. Perhaps target enrichment via hybridization, but
again this may encounter the issue of missing novel or changed
viruses.
Although the NGS method failed to detect all the positive sam-
ples, it did offer several advantages over the RT-PCR method. For
example, the NGS provided more detailed typing information for
the detected viruses including subtype data for RSV and hMPV as
well as serotype data for the HRV and HEV.
Such information is highly informative. As well as enabling
real-time diagnostic data to be produced, NGS could simul-
taneously provide resistance testing (e.g., H275Y mutation of
inﬂuenza A, conferring oseltamivir resistance) and typing data,
as demonstrated here and previously [12,13]. This could be used
to inform public health of circulating strains and could allow
rapid detection of the emergence of novel subtypes (e.g., EV68
and ADV 14) or highlight potential outbreaks. In future, it may
also detect viral polymorphisms associated with disease severity
[14,15].
Similar to other studies we also found a correlation between
NGS sequence reads and RT-PCR cycle thresholds [16,17]. This was
particularly strong for rhinoviruses – mainly because these repre-
sented the majority of the pathogens detected. This suggests that
sequence reads might be a suitable proxy for viral/target copies.
This would enable laboratories/clinicians to interpret the clinical
relevance of results [18]. Such data can also be used to infer prog-
nosis or treatment response.
Viral co-infection detection by NGS could not be assessed in
this cohort as only a single co-infection episode was detected by
RT-PCR. The population under study were normally healthy adults
who did not require health care interventions. There is little infor-
mation on co-infections in such individuals but evidence suggests
that viral co-infections occur more commonly in hospitalised indi-
viduals [19]. The detection of inﬂuenza was also lower than may
have been expected which probably relates to the level vaccina-
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tion amongst the cohort. Further studies including children and
unvaccinated individuals would be of use.
The NGS approach did not detect positive results that were
missed by the RT-PCR. Although this panel was small, our data sup-
ports other studies which have concluded that current respiratory
panels are appropriate for the detection of the main causes of viral
respiratory disease.
Amajorbarrier to the introductionofNGSas a routinediagnostic
test is its cost and turnaround time. The current cost of sequencing
is prohibitive as a diagnostic test when compared to RT-PCR but
this has reduced in recent years, a trend which will probably con-
tinue in the future. Although not designed to detect bacteria the
current method still detected bacterial genomes in nearly all sam-
ples, this ﬁnding shows that syndromic testing is a possibility. If
viral, bacterial and fungal diagnostic tests can be combined into a
single assay this would beneﬁt the cost effectiveness of developing
NGS as a diagnostic tool.
The turnaround-time of the above process was in the region
of seven days, including preliminary data analysis whereas the
turnaround time for RT-PCRmethods is usually just a few hours. As
a result, NGS is unlikely to become a routine diagnostic test in the
near term. However there aremany steps that could be accelerated
with automation. The development of kit based library prepara-
tion methods has also resulted in a condensed process, reducing
hands-on time. Technical advances that allow a greater depth of
sequencing could obviate the need for enrichment processes. Fur-
thermore third generation sequencers, such as the PacBio RS II,
offer the potential for evenmore rapid sequencing. Taken together,
these advances are likely to improve the TRT of NGS signiﬁ-
cantly.
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